EA201692512A1 - Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки - Google Patents
Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точкиInfo
- Publication number
- EA201692512A1 EA201692512A1 EA201692512A EA201692512A EA201692512A1 EA 201692512 A1 EA201692512 A1 EA 201692512A1 EA 201692512 A EA201692512 A EA 201692512A EA 201692512 A EA201692512 A EA 201692512A EA 201692512 A1 EA201692512 A1 EA 201692512A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compositions
- inhibitors
- synthetic
- nanosems
- methods
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 abstract 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 abstract 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 abstract 1
- 229960001438 immunostimulant agent Drugs 0.000 abstract 1
- 239000003022 immunostimulating agent Substances 0.000 abstract 1
- 230000003308 immunostimulating effect Effects 0.000 abstract 1
- 239000002539 nanocarrier Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Раскрыты композиции синтетических наноносителей, содержащие антигены и иммуностимуляторы, а также композиции ингибиторов иммунной контрольной точки и связанные с ними способы введения индивидууму.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462017101P | 2014-06-25 | 2014-06-25 | |
PCT/US2015/037833 WO2015200728A1 (en) | 2014-06-25 | 2015-06-25 | Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201692512A1 true EA201692512A1 (ru) | 2017-07-31 |
Family
ID=53546730
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201692512A EA201692512A1 (ru) | 2014-06-25 | 2015-06-25 | Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки |
Country Status (6)
Country | Link |
---|---|
US (1) | US20150374815A1 (ru) |
EP (1) | EP3160453A1 (ru) |
AU (1) | AU2015279738A1 (ru) |
CA (1) | CA2953507A1 (ru) |
EA (1) | EA201692512A1 (ru) |
WO (1) | WO2015200728A1 (ru) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2010254551B2 (en) | 2009-05-27 | 2016-10-20 | Selecta Biosciences, Inc. | Immunomodulatory agent-polymeric compounds |
NO2575876T3 (ru) | 2010-05-26 | 2018-05-05 | ||
EP2640190A4 (en) | 2010-11-05 | 2016-05-11 | Selecta Biosciences Inc | MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS |
US9511151B2 (en) | 2010-11-12 | 2016-12-06 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
KR20230006042A (ko) | 2011-04-29 | 2023-01-10 | 셀렉타 바이오사이언시즈, 인크. | 항체 반응을 감소시키기 위한 관용원성 합성 나노운반체 |
CA2843274A1 (en) | 2011-07-29 | 2013-02-07 | Selecta Biosciences, Inc. | Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses |
US10988516B2 (en) | 2012-03-26 | 2021-04-27 | Uti Limited Partnership | Methods and compositions for treating inflammation |
US9603948B2 (en) | 2012-10-11 | 2017-03-28 | Uti Limited Partnership | Methods and compositions for treating multiple sclerosis and related disorders |
CN110841067A (zh) | 2013-05-03 | 2020-02-28 | 西莱克塔生物科技公司 | 用于降低的或增强的药效学作用的致耐受性合成纳米载体和治疗性大分子 |
EP3539564A1 (en) | 2013-11-04 | 2019-09-18 | UTI Limited Partnership | Methods and compositions for sustained immunotherapy |
JP2017503803A (ja) | 2014-01-10 | 2017-02-02 | シャンハイ バーディー バイオテック インコーポレイテッド | Egfr発現腫瘍を処置するための化合物及び組成物 |
WO2016004876A1 (en) * | 2014-07-09 | 2016-01-14 | Shanghai Birdie Biotech, Inc. | Anti-pd-l1 combinations for treating tumors |
CN107073091A (zh) | 2014-09-07 | 2017-08-18 | 西莱克塔生物科技公司 | 用于减弱外显子跳读抗病毒转移载体免疫应答的方法和组合物 |
KR20180011135A (ko) | 2015-05-06 | 2018-01-31 | 유티아이 리미티드 파트너쉽 | 지속 치료를 위한 나노입자 조성물 |
CN115554406A (zh) | 2016-01-07 | 2023-01-03 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-cd20组合 |
CN115252792A (zh) | 2016-01-07 | 2022-11-01 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-egfr组合 |
CA3013880A1 (en) * | 2016-02-10 | 2017-08-17 | Pfizer Inc. | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same |
BR112019018748A2 (pt) | 2017-03-11 | 2020-04-07 | Selecta Biosciences Inc | métodos e composições relacionados ao tratamento combinado com anti-inflamatórios e nanocarreadores sintéticos compreendendo um imunossupressor |
WO2018181542A1 (ja) * | 2017-03-29 | 2018-10-04 | テルモ株式会社 | アジュバント組成物およびこれを含むワクチン組成物並びに薬剤キット |
CN108794467A (zh) | 2017-04-27 | 2018-11-13 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
WO2018209017A1 (en) * | 2017-05-10 | 2018-11-15 | The General Hospital Corporation | Cancer treatment with a cxcl12 signaling inhibitor and an immune checkpoint inhibitor |
JP7080501B2 (ja) | 2017-06-23 | 2022-06-06 | バーディー バイオファーマシューティカルズ インコーポレイテッド | 医薬品組成物 |
EP4149550A1 (en) * | 2020-05-15 | 2023-03-22 | The Board of Trustees of the Leland Stanford Junior University | Toll-like receptor (tlr) agonist nanoparticles and uses thereof |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946929A (en) | 1983-03-22 | 1990-08-07 | Massachusetts Institute Of Technology | Bioerodible articles useful as implants and prostheses having predictable degradation rates |
US4638045A (en) | 1985-02-19 | 1987-01-20 | Massachusetts Institute Of Technology | Non-peptide polyamino acid bioerodible polymers |
US4806621A (en) | 1986-01-21 | 1989-02-21 | Massachusetts Institute Of Technology | Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article |
CA1340581C (en) | 1986-11-20 | 1999-06-08 | Joseph P. Vacanti | Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices |
US5736372A (en) | 1986-11-20 | 1998-04-07 | Massachusetts Institute Of Technology | Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure |
US5804178A (en) | 1986-11-20 | 1998-09-08 | Massachusetts Institute Of Technology | Implantation of cell-matrix structure adjacent mesentery, omentum or peritoneum tissue |
US5019379A (en) | 1987-07-31 | 1991-05-28 | Massachusetts Institute Of Technology | Unsaturated polyanhydrides |
US6130082A (en) | 1988-05-05 | 2000-10-10 | American Cyanamid Company | Recombinant flagellin vaccines |
US5010167A (en) | 1989-03-31 | 1991-04-23 | Massachusetts Institute Of Technology | Poly(amide-and imide-co-anhydride) for biological application |
US5399665A (en) | 1992-11-05 | 1995-03-21 | Massachusetts Institute Of Technology | Biodegradable polymers for cell transplantation |
US5512600A (en) | 1993-01-15 | 1996-04-30 | Massachusetts Institute Of Technology | Preparation of bonded fiber structures for cell implantation |
US5514378A (en) | 1993-02-01 | 1996-05-07 | Massachusetts Institute Of Technology | Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
US5565215A (en) | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6007845A (en) | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
US5716404A (en) | 1994-12-16 | 1998-02-10 | Massachusetts Institute Of Technology | Breast tissue engineering |
US6123727A (en) | 1995-05-01 | 2000-09-26 | Massachusetts Institute Of Technology | Tissue engineered tendons and ligaments |
US6095148A (en) | 1995-11-03 | 2000-08-01 | Children's Medical Center Corporation | Neuronal stimulation using electrically conducting polymers |
US5902599A (en) | 1996-02-20 | 1999-05-11 | Massachusetts Institute Of Technology | Biodegradable polymer networks for use in orthopedic and dental applications |
EP0938315B9 (en) | 1996-10-25 | 2008-02-20 | Minnesota Mining And Manufacturing Company | Immune response modifier compounds for treatment of th2 mediated and related diseases |
US6211159B1 (en) | 1997-04-11 | 2001-04-03 | University Of Toronto | Flagellin gene, FlaC of campylobacter |
US5837752A (en) | 1997-07-17 | 1998-11-17 | Massachusetts Institute Of Technology | Semi-interpenetrating polymer networks |
NZ504800A (en) | 1997-11-28 | 2001-10-26 | Sumitomo Pharma | 6-Amino-9-benzyl-8-hydroxy-purine derivatives and interferon inducers, antiviral agents, anticancer agents and therapeutic agents for immunologic diseases thereof |
US6506577B1 (en) | 1998-03-19 | 2003-01-14 | The Regents Of The University Of California | Synthesis and crosslinking of catechol containing copolypeptides |
US6632922B1 (en) | 1998-03-19 | 2003-10-14 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
US6686446B2 (en) | 1998-03-19 | 2004-02-03 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
US7223398B1 (en) | 1999-11-15 | 2007-05-29 | Dynavax Technologies Corporation | Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof |
CA2400172C (en) | 2000-02-28 | 2010-04-20 | Genesegues, Inc. | Nanocapsule encapsulation system and method |
US20030129251A1 (en) | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
EP1278542A2 (en) | 2000-05-05 | 2003-01-29 | Cytos Biotechnology AG | Molecular antigen arrays and vaccines |
US7192725B2 (en) | 2000-05-19 | 2007-03-20 | University Of Toronto | Flagellin gene, flaC of Campylobacter |
CA2319928A1 (en) | 2000-09-18 | 2002-03-18 | Vasogen Ireland Limited | Apoptosis-mimicking synthetic entities and use thereof in medical treatments |
GB0025414D0 (en) | 2000-10-16 | 2000-11-29 | Consejo Superior Investigacion | Nanoparticles |
US6818732B2 (en) | 2001-08-30 | 2004-11-16 | The Regents Of The University Of California | Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers |
CA2480775C (en) | 2002-04-04 | 2016-05-31 | Coley Pharmaceutical Gmbh | Immunostimulatory g,u-containing oligoribonucleotides |
BRPI0408623A (pt) | 2003-03-26 | 2006-03-07 | Cytos Biotechnology Ag | conjugados de partìcula semelhante ao vìrus análogo de peptìdeo de melan-a |
KR102005840B1 (ko) | 2003-12-19 | 2019-07-31 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | 소프트 또는 임프린트 리소그래피를 이용하여 분리된 마이크로- 및 나노- 구조를 제작하는 방법 |
EP1720568A2 (en) | 2004-02-19 | 2006-11-15 | Coley Pharmaceutical Group, Inc. | Immunostimulatory viral rna oligonucleotides |
JP2008512350A (ja) | 2004-07-01 | 2008-04-24 | イェール ユニバーシティ | 標的化され、そして高密度で薬物が負荷されるポリマー性物質 |
MY159370A (en) | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
AU2006241149A1 (en) | 2005-04-26 | 2006-11-02 | Coley Pharmaceutical Gmbh | Modified oligoribonucleotide analogs with enhanced immunostimulatory activity |
EP1957647B1 (en) | 2005-11-25 | 2015-03-04 | Zoetis Belgium S.A. | Immunostimulatory oligoribonucleotides |
WO2008033432A2 (en) | 2006-09-12 | 2008-03-20 | Coley Pharmaceutical Group, Inc. | Immune modulation by chemically modified ribonucleosides and oligoribonucleotides |
AU2008236566A1 (en) | 2007-04-09 | 2008-10-16 | Chimeros, Inc. | Self-assembling nanoparticle drug delivery system |
WO2008127532A1 (en) | 2007-04-12 | 2008-10-23 | Emory University | Novel strategies for delivery of active agents using micelles and particles |
ES2627233T3 (es) | 2007-10-12 | 2017-07-27 | Massachusetts Institute Of Technology | Nanotecnología de vacunas |
EP2262489A2 (en) | 2008-02-28 | 2010-12-22 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Hollow nanoparticles and uses thereof |
UA103195C2 (ru) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Производные пурина для применения в лечении аллергий, воспалительных и инфекционных заболеваний |
WO2010018132A1 (en) | 2008-08-11 | 2010-02-18 | Smithkline Beecham Corporation | Compounds |
WO2010047839A1 (en) | 2008-10-25 | 2010-04-29 | Aura Biosciences | Modified plant virus particles and uses therefor |
NO2575876T3 (ru) | 2010-05-26 | 2018-05-05 | ||
CN114225019A (zh) | 2013-03-15 | 2022-03-25 | 宾夕法尼亚大学理事会 | 癌疫苗及使用其的治疗方法 |
-
2015
- 2015-06-25 AU AU2015279738A patent/AU2015279738A1/en not_active Abandoned
- 2015-06-25 WO PCT/US2015/037833 patent/WO2015200728A1/en active Application Filing
- 2015-06-25 US US14/751,106 patent/US20150374815A1/en not_active Abandoned
- 2015-06-25 EA EA201692512A patent/EA201692512A1/ru unknown
- 2015-06-25 CA CA2953507A patent/CA2953507A1/en not_active Abandoned
- 2015-06-25 EP EP15738198.9A patent/EP3160453A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP3160453A1 (en) | 2017-05-03 |
US20150374815A1 (en) | 2015-12-31 |
AU2015279738A1 (en) | 2016-12-22 |
WO2015200728A1 (en) | 2015-12-30 |
CA2953507A1 (en) | 2015-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201692512A1 (ru) | Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки | |
EA201691582A1 (ru) | Новые фармацевтические препараты | |
EA201790180A1 (ru) | Способы и терапевтические комбинации для лечения опухолей | |
EA201891083A1 (ru) | Составы антител к cd38 для подкожного введения и их применение | |
EA201790932A1 (ru) | Дозировка и введение нефукозилированных анти-cd40 антител | |
BR112019001607A2 (pt) | inibidores macrocíclicos de quinases | |
EA201790413A1 (ru) | Антитела против tigit | |
EA201890093A1 (ru) | Комбинированная терапия гемобластозов антителами к cd38 и ингибиторами сурвивина | |
EA201691974A1 (ru) | Антитела против ox40 и способы их применения | |
EA201591591A1 (ru) | Соединения карбазола, применяемые в качестве ингибиторов бромодомена | |
EA201692203A1 (ru) | Соединения, ингибирующие tank-связывающую киназу | |
EA201790630A1 (ru) | Способы получения рибозидов | |
EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
EA201691988A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
EA201691610A8 (ru) | Анти-jagged1 антитела и способы применения | |
BR112016028891A2 (pt) | processos de trens de sementes e usos dos mesmos | |
EA201592106A2 (ru) | Локальное сопутствующее введение толерогенных синтетических наноносителей для снижения гиперчувствительности типа i и гиперчувствительности типа iv | |
EA201692425A1 (ru) | Модифицированные биополимеры и способы их получения и использования | |
EA201691594A1 (ru) | Циклопропиламины в качестве ингибиторов lsd1 | |
EA201890530A1 (ru) | Конъюгаты антитела к dll3 и лекарственного средства и способы их применения | |
AR104847A1 (es) | Formulación de anticuerpo anti-cgrp | |
EA201691259A1 (ru) | РЕГУЛЯТОРЫ Nrf2 | |
EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
EA201692529A1 (ru) | Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов | |
EA201791095A1 (ru) | Способ лечения рака |